PCIA
CRBU icon

Prime Capital Investment Advisors’s Caribou Biosciences CRBU Stock Holding History

Prime Capital Investment Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.4K Sell
32,315
-1,619
-5% -$2.78K ﹤0.01% 1018
2025
Q4 		$54K Sell
33,934
-740
-2% -$1.55K ﹤0.01% 1001
2025
Q3 		$80.8K Sell
34,674
-3,319
-9% -$6.27K ﹤0.01% 974
2025
Q2 		$47.9K Sell
37,993
-15,986
-30% -$15.7K ﹤0.01% 931
2025
Q1 		$49.3K Sell
53,979
-1,783
-3% -$2.32K ﹤0.01% 1027
2024
Q4 		$88.7K Buy
55,762
+40,291
+260% +$81K ﹤0.01% 898
2024
Q3 		$30.3K Sell
15,471
-547
-3% -$1.12K ﹤0.01% 906
2024
Q2 		$26.3K Sell
16,018
-292
-2% -$933 ﹤0.01% 912
2024
Q1 		$83.8K Sell
16,310
-1,366
-8% -$8.42K ﹤0.01% 967
2023
Q4 		$101K Sell
17,676
-18,787
-52% -$92.9K ﹤0.01% 913
2023
Q3 		$174K Sell
36,463
-3,854
-10% -$23.9K ﹤0.01% 698
2023
Q2 		$171K Buy
40,317
+13,986
+53% +$62.8K ﹤0.01% 715
2023
Q1 		$140K Buy
+26,331
New +$164K 0.01% 519

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prime Capital Investment Advisors's CRBU Position: Q1 2026 in Review

Prime Capital Investment Advisors reduced its Caribou Biosciences (CRBU) stake by 4.8% in Q1 2026, selling an estimated $2.78K and leaving 32,315 shares worth $61.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1018.

Prime Capital Investment Advisors first reported a position in CRBU in Q1 2023 and has held it in 13 quarters since. The position peaked at $174K in Q3 2023. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Prime Capital Investment Advisors held 32,315 shares of Caribou Biosciences worth $61.4K as of Q1 2026.
  • Prime Capital Investment Advisors sold 1,619 Caribou Biosciences shares in Q1 2026, an estimated $2.78K.
  • Caribou Biosciences made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #1018 holding.
  • Prime Capital Investment Advisors first reported a position in Caribou Biosciences in Q1 2023 and has held it in 13 quarters since.
  • Prime Capital Investment Advisors's Caribou Biosciences position peaked at $174K in Q3 2023.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.